A comparative study of mexidol and mexiprim pharmacokinetic parameters

Shchulkin A.V.; Yakusheva E.N.; Chernykh I.V.

doi:https://doi.org/10.17116/jnevro201411411240-43

Shchulkin A.V.

Ryazan State Medical University, Ryazan, Russia

Yakusheva E.N.

Ryazan State Medical University, Ryazan, Russia

Chernykh I.V.

Ryazan State Medical University, Ryazan, Russia

A comparative study of mexidol and mexiprim pharmacokinetic parameters

Authors:

Shchulkin A.V., Yakusheva E.N., Chernykh I.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11‑2): 40‑43

DOI: 10.17116/jnevro201411411240-43

Read: 31628 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Shchulkin AV, Yakusheva EN, Chernykh IV. A comparative study of mexidol and mexiprim pharmacokinetic parameters. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11‑2):40‑43. (In Russ.)
https://doi.org/10.17116/jnevro201411411240-43

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Modern approaches to diagnosis and treatment of syndrome of autonomic dysfunction in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11-2):66-75

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

Study of the features of perchlozon isolation from biological fluids for the purposes of chemico-toxicological analysis. Forensic Medical Expertise. 2024;(6):38-41

Modern aspects of chronic cerebral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113

Arterial hypertension is an oxidative stress, as a pathogenetic target for the treatment of chronic cerebrovascular insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):84-90

The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112

Personal characteristics of patients with cerebral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56

Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52

The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33

The impact of Mexidol on improving quality of life parameters and functional kidney status as part of complex therapy for cognitive impairments in comorbid patients with microalbuminuria against the background of arterial hypertension and type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):478-478

Abstract:

Objective. To compare pharmacokinetic parameters of mexidol (coated tablets, "Farmasoft") and mexiprim (tablets film-coated, "STADA CIS"). Material and methods. The study included 14 adult male Chinchilla rabbits. Concentration of 2-ethyl-6-methyl-3-hydroxypyridine succinate in the blood plasma of animals was analyzed using HPLC with UV detection. Results and conclusion. Mexidol as compared to mexiprim was more completely and rapidly absorbed from the gastrointestinal tract, it was confirmed by the higher value of maximal concentration of 2-ethyl-6-methyl-3-hydroxypyridine succinate and less maximal concentration time after mexidol administration. The drugs had similar excretion that was confirmed by the lack of significant differences in the values of total clearance, half-life, and the average retention time.

Keywords:

mexidol

mexiprim

pharmacokinetic

HPLC

Authors:

Shchulkin A.V.

Ryazan State Medical University, Ryazan, Russia

Yakusheva E.N.

Ryazan State Medical University, Ryazan, Russia

Chernykh I.V.

Ryazan State Medical University, Ryazan, Russia

Close metadata

References:

European Medicines Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP), Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98, July 2001.
U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products - general considerations. Washington 2003.
Voronina T.A. Meksidol: spektr farmakologicheskikh effektov. Zhurn nevrol i psikhiat 2012; 112: 12: 86-90.
Sariev A.K. Farmakokinetika proizvodnykh 3-oksipiridina v eksperimente: Avtoref. dis. ... kand. med. nauk. M 1987.
Shchul'kin A.V., Yakusheva E.N., Chernykh I.V. Raspredelenie meksidola v strukturakh golovnogo mozga, ego kletochnykh elementakh i subkletochnykh fraktsiyakh. Zhurn nevrol i psikhiat 2014; 114: 8: 69-72.
El. rezhim dostupa: http://www.mexidol.ru/files/__1.pdf
El. rezhim dostupa: http://stada.ru/products/meksiprim.html
Gavrilov A.S., Gusel'nikova E.V., Koneva L.A., Bakharev V.P., Petrov A.Yu. Razrabotka metoda polucheniya i testirovaniya polimernykh plenok s tsel'yu optimizatsii plenochnogo pokrytiya tabletok. Khim-farm zhurn 2003; 37: 6: 54-56.
Egoshina Yu.A., Potselueva L.A. Sovremennye vspomogatel'nye veshchestva v tabletochnom proizvodstve. Uspekhi sovremen estestv 2009; 10: 23-26.
Gohary O.M. In vitro adsorption of mebeverine hydrochloride onto kaolin and its relationship to pharmacological effects of the drug in vivo. Pharm Act Helv 1997; 72: 1: 11-21.